Showing 3231-3240 of 5621 results for "".
- On World Sight Day, Orbis International Calls for “All Eyes on 2020” and Preserving the Future of Visionhttps://modernod.com/news/on-world-sight-day-orbis-international-calls-for-all-eyes-on-2020-and-preserving-the-future-of-vision/2476936/Today, Orbis International commemorates World Sight Day by celebrating achievements of the eye health community over the past two decades, and warning of a projected global tripling of blindness over the next 30 years. Next year is a critical year for Orbis International and other leaders
- Cataract Surgery Products Continue to be the Main Single-Use Surgical Device Sales Driverhttps://modernod.com/news/cataract-surgery-products-continue-to-be-the-main-single-use-surgical-device-sales-driver/2476905/The world’s aging population—leading to steady growth in cataract surgeries—and rising concerns over cross-contamination are key factors that will drive healthy growth in the single-use ophthalmic surgical product mar
- Novartis Announces Details of TALON Global Clinical Trial in Wet AMD Comparing Brolucizumab vs Aflibercepthttps://modernod.com/news/novartis-announces-details-of-talon-global-clinical-trial-in-wet-amd-comparing-brolucizumab-vs-aflibercept/2476870/In the phase 3b TALON clinical trial, Novartis announced that the two primary endpoints are superiority for brolucizumab in treatment interval duration and noninferiority in change in visual acuity. Secondary endpoints will examine durability and anatomical outcomes, including retinal fluid resol
- NHS England to Fund Novartis’ Gene Therapy Luxturna for Inherited Retinal Diseasehttps://modernod.com/news/nhs-england-to-fund-novartis-gene-therapy-luxturna-for-inherited-retinal-disease/2476855/NHS England announced Wednesday funding for Novartis’ Luxturna (voretigene neparvovec) after agreeing a deal with the company that will provide access to the gene therapy from January 2020. The one-time treatment gained European Commission approval last year for patients with vision loss du
- Rayner Acquires Stake in Reper to Drive R&D and Build Presence in Russiahttps://modernod.com/news/rayner-acquires-stake-in-reper-to-drive-rd-and-build-presence-in-russia/2476854/Following a 4-year R&D collaboration on a novel hydrophobic IOL material, Rayner has acquired a stake in Reper, a material science and medical device company based in Russia. Terms of the deal were not disc
- OKYO Pharma Announces Potent Anti-inflammatory Effects of OK-113 in a Mouse Model of Dry Eye Diseasehttps://modernod.com/news/okyo-pharma-announces-potent-anti-inflammatory-effects-of-ok-113-in-a-mouse-model-of-dry-eye-disease/2476830/OKYO Pharma has announced potent anti-inflammatory activity of OK-113, an in-house discovered proprietary agonist of Chemerin GPCR, in an experimental model of dry eye disease (DED) in mice. These preclinical efficacy data, identifying a lead drug candidate, will facilitate initiation of clinical
- Glaukos Announces Agreement to Buy Avedro in All-Stock Dealhttps://modernod.com/news/glaukos-announces-agreement-to-buy-avedro-in-all-stock-deal/2479551/In a move to diversify its offerings and expand its corneal health franchise, Glaukos agreed to acquire cross-linking company Avedro in an all-stock transaction.
- Forbes: Will Your iPhone’s Dark Mode Save Your Eyes?https://modernod.com/news/forbes-will-your-iphones-dark-mode-save-your-eyes/2476786/Eye care has come a long way. From cataract surgery to Lasik, we can do more than ever before to return sight to those who once would have lost it. These days, it seems like there’s always a new breakthrough around the corner—here’s a roundup of some of the biggest trends in eye care and what the
- Harrow Health Forms Stowe Pharmaceuticals Subsidiary to Develop Anti-Microbial Ophthalmic and Otic Therapeuticshttps://modernod.com/news/harrow-health-forms-stowe-pharmaceuticals-subsidiary-to-develop-anti-microbial-ophthalmic-and-otic-therapeutics/2479553/Harrow Health announced that its newly formed subsidiary, Stowe Pharmaceuticals, has entered into an agreement with TGV Health to acquire worldwide rights to the Zian anti-microbial molecule for ophthalmic and otic uses. Zian is a patented small molecule that is water soluble, colorless,
- Genentech/Roche Complete Enrollment in Archway Phase 3 Study of the Port Delivery System with Ranibizumab in Wet AMDhttps://modernod.com/news/genentech-roche-complete-enrollment-in-archway-phase-3-study-of-the-port-delivery-system-with-ranibizumab-in-wet-amd/2476737/Genentech and Roche have completed patient enrollment in the phase 3 Archway (